GSE29431 Expression Data

Identifying breast cancer biomarkers.

Background: Breast cancer is a heterogeneous neoplasm. Distinct subtypes of breast cancer have been defined, suggesting the existence of molecular differences contributing to their clinical outcomes. However, the molecular differences between HER2 positive and negative breast cancer tumors remain unclear. Objective: The aim of this study was to identify a gene expression profile for breast tumors based on HER2 status. Material and methods: The HER2 status was determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in 54 breast tumor samples. Using Affymetrix microarray data from these breast tumors, we established the expression profiling of breast cancer based on HER2 IHC and FISH results. To validate microarray experiment data, real-time quantitative reverse transcription-PCR was performed. Results: We found significant differences between the HER2-positive and HER2-negative breast tumor samples, which included overexpression of HER2, as well as other genes located on 17q12, and genes functionally related to migration. Conclusion: Our study shows the potential of integrated genomics profiling to shed light on the molecular knowledge of HER2-positive breast tumors.

乳腺癌生物标志物的鉴定
背景：乳腺癌是一类异质性肿瘤。目前已明确划分出多种乳腺癌亚型，提示存在影响其临床转归的分子差异。然而，HER2阳性与HER2阴性乳腺癌肿瘤之间的分子差异仍未明确。
研究目的：本研究旨在基于HER2状态鉴定乳腺肿瘤的基因表达谱。
材料与方法：通过免疫组织化学（immunohistochemistry, IHC）与荧光原位杂交（fluorescence in situ hybridization, FISH）检测54份乳腺肿瘤样本的HER2状态。利用上述样本的Affymetrix微阵列数据，我们根据HER2免疫组化与荧光原位杂交结果构建了乳腺癌表达谱。为验证微阵列实验数据，本研究实施了实时定量逆转录聚合酶链式反应（real-time quantitative reverse transcription-PCR）。
结果：本研究发现HER2阳性与HER2阴性乳腺肿瘤样本间存在显著表达差异，涉及HER2基因、17q12染色体区域的其他基因以及与细胞迁移功能相关基因的过表达。
结论：本研究证实，整合基因组谱学分析可为解析HER2阳性乳腺癌的分子机制提供新的视角。